Prime Medicine, Inc. (NASDAQ:PRME – Get Free Report) was down 5.6% on Monday . The stock traded as low as $4.15 and last traded at $4.18. Approximately 759,955 shares were traded during trading, a decline of 77% from the average daily volume of 3,331,140 shares. The stock had previously closed at $4.43.
Wall Street Analysts Forecast Growth
Several equities analysts have commented on PRME shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Prime Medicine in a research note on Monday, December 29th. Lifesci Capital upgraded shares of Prime Medicine to a “strong-buy” rating in a report on Tuesday, December 23rd. Finally, Wall Street Zen cut Prime Medicine from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy”.
Prime Medicine Stock Down 5.8%
Prime Medicine (NASDAQ:PRME – Get Free Report) last announced its quarterly earnings data on Friday, November 7th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). The business had revenue of $1.23 million during the quarter. Prime Medicine had a negative net margin of 3,301.64% and a negative return on equity of 163.51%.
About Prime Medicine
We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof.
See Also
- Five stocks we like better than Prime Medicine
- Your Signature Is Missing – Act Before It’s Too Late
- Buy This Stock at 9:30 AM on MONDAY!
- What Expenses Can Be Deducted From Capital Gains Tax?
- Buy this Gold Stock Before May 2026
- Do not delete, read immediately
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
